Should drugmakers amp up security at leaked plants?

When WikiLeaks leaks, it's more like a flood, and this time, it's even covering pharma. The latest revelations to float to the surface include a list of "critical" drug and vaccine facilities in countries around the world. Among these key plants are Big Pharma facilities in Europe, Latin America, Canada and Australia that are operated by drugmakers including Roche and GlaxoSmithKline ($GSK).

Destruction of those facilities would be a threat to national security and/or public health and safety, the government decided in 2008. That's because they make essential products, such as smallpox vaccines, diabetes drugs, and flu treatments (Roche's Tamiflu and GSK's Relenza among them). Plants turning out insulin for Sanofi-Aventis ($SNY) and Novo Nordisk ($NVO) made the list, as did facilities run by Genzyme ($GENZ) and Novartis.

Government officials decried the identification of these critical facilities, calling it "irresponsible" and even "bordering on criminal," ostensibly because the list puts a bulls-eye on every one of them. In fact, one commentator suggested that companies double-check their security procedures at the named plants, InPharm notes. If drugmakers are doing so, they aren't saying. But then again, they aren't saying much of anything about the leaks.

- read the InPharm story

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.